Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review

Date: May 2, 2017
Pages: 48
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: BFFC7371C30EN
Leaflet:

Download PDF Leaflet

Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review
Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

Boehringer Ingelheim GmbH (Boehringer), a subsidiary of C. H. Boehringer Sohn AG & Co KG is a pharmaceutical company, which carries out research, development, manufacture and sale of pharmaceuticals. The company offers a wide range of products including prescription medicines, consumer health care products, animal health care products and biopharmaceuticals. Its products are used in the treatment of central nervous system disorders, respiratory diseases, cardiovascular diseases, metabolic disorders, cancer, urological and viral conditions, among others. The company focuses on the research, development, manufacture and marketing of new drugs of therapeutic value for human and veterinary medicine. Boehringer operates globally through affiliates and is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.

Boehringer Ingelheim GmbH Key Recent Developments

Mar 13,2017: FORMA Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim
Mar 02,2017: Boehringer Ingelheim sponsors the new building of the Research Institute of Molecular Pathology in Vienna with EUR 52 million
Jan 23,2017: Inovalon Announces Agreement With Boehringer Ingelheim to Support Outcome-Based Contracting
Nov 30,2016: Boehringer Ingelheim Selects ACD/Labs for International Deployment
Oct 18,2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

Boehringer Ingelheim GmbH - Key Facts
Boehringer Ingelheim GmbH - Key Employees
Boehringer Ingelheim GmbH - Key Employee Biographies
Boehringer Ingelheim GmbH - Major Products and Services
Boehringer Ingelheim GmbH - Pharmaceutical Pipeline Products Data
Boehringer Ingelheim GmbH, Pipeline Products by Therapy Area
Boehringer Ingelheim GmbH, Pipeline Products by Development Phase
Boehringer Ingelheim GmbH - History
Boehringer Ingelheim GmbH - Company Statement
Boehringer Ingelheim GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Boehringer Ingelheim GmbH - Business Description
Boehringer Ingelheim GmbH - Corporate Strategy
Boehringer Ingelheim GmbH - SWOT Analysis
SWOT Analysis - Overview
Boehringer Ingelheim GmbH - Strengths
Boehringer Ingelheim GmbH - Weaknesses
Boehringer Ingelheim GmbH - Opportunities
Boehringer Ingelheim GmbH - Threats
Boehringer Ingelheim GmbH - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Boehringer Ingelheim GmbH, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Mar 13, 2017: FORMA Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim
Mar 02, 2017: Boehringer Ingelheim sponsors the new building of the Research Institute of Molecular Pathology in Vienna with EUR 52 million
Jan 23, 2017: Inovalon Announces Agreement With Boehringer Ingelheim to Support Outcome-Based Contracting
Nov 30, 2016: Boehringer Ingelheim Selects ACD/Labs for International Deployment
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers
Aug 03, 2016: Boehringer Ingelheim: Growth in all core businesses
Jul 20, 2016: The European Stroke Organisation and Boehringer Ingelheim launch the “Angels Initiative”, a unique healthcare initiative to improve acute stroke care across Europe
Jul 04, 2016: Gaia Novarino wins Boehringer Ingelheim’s FENS Award 2016 for Exceptional Research in Neuroscience
Jun 10, 2016: Simone Menne – new Member of the Board of Managing Directors of Boehringer Ingelheim/Responsible for Corporate Board Division Finance
May 23, 2016: Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Boehringer Ingelheim GmbH, Key Facts
Boehringer Ingelheim GmbH, Key Employees
Boehringer Ingelheim GmbH, Key Employee Biographies
Boehringer Ingelheim GmbH, Major Products and Services
Boehringer Ingelheim GmbH, Number of Pipeline Products by Therapy Area
Boehringer Ingelheim GmbH, Number of Pipeline Products by Development Stage
Boehringer Ingelheim GmbH, History
Boehringer Ingelheim GmbH, Other Locations
Boehringer Ingelheim GmbH, Subsidiaries
Boehringer Ingelheim GmbH, Key Competitors
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Boehringer Ingelheim GmbH, Recent Deals Summary

LIST OF FIGURES

Boehringer Ingelheim GmbH, Pipeline Products by Therapy Area
Boehringer Ingelheim GmbH, Pipeline Products by Development Phase
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Phibro Animal Health Corp
Pfizer Inc
Novartis AG
Jurgen Schmidt Chemievertretung GmbH
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
Bristol-Myers Squibb Company
Bayer HealthCare AG
Skip to top


OSRAM GmbH - Strategic SWOT Analysis Review US$ 125.00 Feb, 2015 · 37 pages
Oiltanking GmbH - Strategic SWOT Analysis Review US$ 125.00 Feb, 2017 · 30 pages

Ask Your Question

Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: